Patents by Inventor Ozlem Tureci

Ozlem Tureci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8425902
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: April 23, 2013
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat
    Inventors: Ugur Sahin, Ozlem Tureci, Gunda Brandenburg, Dirk Usener
  • Publication number: 20130071325
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.
    Type: Application
    Filed: March 10, 2011
    Publication date: March 21, 2013
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Rita Mitnacht-Kraus
  • Patent number: 8399210
    Abstract: According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful for diagnosis and treatment. A brain-specific expression of the autoantigens further emphasizes an important role of the antigens and antibodies in the origin and development of neurological autoimmune diseases.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: March 19, 2013
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat
    Inventors: Ugur Sahin, Özlem Türeci, Alexander Zaigler
  • Publication number: 20130052217
    Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
    Type: Application
    Filed: March 9, 2011
    Publication date: February 28, 2013
    Inventors: Thorsten Klamp, Ugur Sahin, Ozlem Tureci, Michael Koslowski, Thomas Hiller, Jens Schumacher
  • Patent number: 8354104
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: January 15, 2013
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg—Universitat
    Inventors: Ugur Sahin, Michael Koslowski, Ozlem Tureci
  • Publication number: 20130011426
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: May 15, 2012
    Publication date: January 10, 2013
    Inventors: Özlem Türeci, Ugur Sahin, Sebastian Kreiter
  • Publication number: 20120308478
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Application
    Filed: November 11, 2010
    Publication date: December 6, 2012
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
  • Publication number: 20120258091
    Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
    Type: Application
    Filed: November 15, 2011
    Publication date: October 11, 2012
    Applicant: GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Publication number: 20120219991
    Abstract: The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject.
    Type: Application
    Filed: October 29, 2010
    Publication date: August 30, 2012
    Inventors: Ugur Sahin, Ozlem Tureci, Torsten Seppmann, Holger Hoff, Jens Schumacher
  • Publication number: 20120195830
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Application
    Filed: March 21, 2012
    Publication date: August 2, 2012
    Applicants: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
  • Publication number: 20120165390
    Abstract: The present invention is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies. The present invention also includes methods which make possible to assess and/or prognose the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 28, 2012
    Applicants: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Publication number: 20120164160
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Application
    Filed: November 29, 2011
    Publication date: June 28, 2012
    Applicants: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
  • Patent number: 8178653
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the transmembrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: May 15, 2012
    Assignee: BioNTech AG
    Inventors: Özlem Türeci, Ugur Sahin, Sebastian Kreiter
  • Patent number: 8168427
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Grant
    Filed: November 24, 2006
    Date of Patent: May 1, 2012
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Dirk Usener, Stefan Fritz, Cristoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schroder, Philippe Thiel
  • Publication number: 20120070430
    Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Application
    Filed: April 22, 2010
    Publication date: March 22, 2012
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
  • Publication number: 20120014948
    Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
    Type: Application
    Filed: July 18, 2011
    Publication date: January 19, 2012
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Patent number: 8088913
    Abstract: The present invention is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies. The present invention also includes methods which make possible to assess and/or prognose the metastatic behavior of a cancer disease and/or the occurrence of a relapse of cancer.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: January 3, 2012
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Patent number: 8088588
    Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: January 3, 2012
    Assignee: Ganymed Pharmaceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Publication number: 20110311584
    Abstract: The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).
    Type: Application
    Filed: December 9, 2009
    Publication date: December 22, 2011
    Inventors: Ugur Sahin, Özlem Türeci, Sebastian Kreiter, Abderraouf Selmi
  • Publication number: 20110300144
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Application
    Filed: February 19, 2010
    Publication date: December 8, 2011
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Wöll, Gabriela-Elena Oprea